IL6 and systemic-onset juvenile idiopathic arthritis: Secondly, diseases for which the IL-6 level is correlated with disease activity may be ameliorated by IL-6 inhibition, as evidenced by Castleman disease, RA, sJIA and large vessel vasculitis.